Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 3/20 | 0.38 |
| ▸ | MC3R | P41968 | 3/20 | 0.38 |
| ▸ | MC1R | Q01726 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867815 | 0.94 | GHSR (0.54) | GHSROPRD1MC4RMC3RMC1R | |
| SCHEMBL867816 | 0.94 | GHSR (0.54) | GHSROPRD1MC4RMC3RMC1R | |
| SCHEMBL10039200 | 0.89 | GHSR (0.66) | GHSROPRD1 | |
| SCHEMBL867796 | 0.89 | GHSR (0.56) | GHSROPRD1 | |
| SCHEMBL867797 | 0.89 | GHSR (0.56) | GHSROPRD1 | |
| SCHEMBL10039194 | 0.88 | GHSR (0.41) | GHSROPRD1MC4RMC3RMC1R | |
| SCHEMBL1401210 | 0.88 | GHSR (0.56) | GHSROPRD1 | |
| SCHEMBL1401184 | 0.88 | GHSR (0.56) | GHSROPRD1 | |
| SCHEMBL867658 | 0.87 | GHSR (0.55) | GHSROPRD1 | |
| SCHEMBL14106527 | 0.87 | GHSR (0.55) | GHSROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077745-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885OPRD1 57/4885MC4R 21/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | GHSR 1/4885OPRD1 3939/4885MC4R 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.